HIGHLIGHTS
- What: The authors aimed to collect and analyze real-world experience from patients treated with PRRT, many of whom are heavily pretreated and have multiple co-morbidities.
- Who: Vineeth Sukrithan and colleagues from the Editor: Ismaheel Lawal, Emory University, UNITED have published the paper: Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience, in the Journal: PLOS ONE of 17/08/2023
- Future: Studies are needed to understand the mechanism underlying this toxicity.
SUMMARY
The trial enrolled patients with well-differentiated mid-gut . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.